Biometrix Technology Inc. of Chuncheon-si, Gangwon-do at MEDICA 2020 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Biometrix Technology Inc.

2-2-ho, 56, Soyanggang-ro, 24232 Chuncheon-si, Gangwon-do
Korea, Republic
Telephone +82 33 2586097
Fax +82 22 2586099

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.


Chanyung Hur



Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Our products

Product category: Immuno assay testing

9G test™ Cancer/Lung

· 9G test™ Cancer/Lung and LDCT are serviced at the same time, 80% of suspected lung cancer patients will be judged normal, and 20% of lung nodules, including stage 0~1 lung cancer, will be sent to next stage, confirmed examination.

· The confirmed test included stage 0~1 lung cancer, increasing the five-year survival rate.

· The purpose of the 9G test™ Cancer/Lung is to allow doctors to request a thorough examination of suspected stage 1 lung cancer patients.

More Less

Product category: Immuno assay testing

MTBDR-RIF 9G Membrane Kit™

Diagnosing Tuberculosis and MTBDR-RIF with a single PCR.

· Detection of M.Tuberculosis and the identification of rpoB gene mutations (531, 526, 522, 516, 511) that induce drug resistance to Rifampin.

· MTBDR-RIF 9G membrane KIT™ detects M.Tuberculosis very sensitively (Limit of Detection: 10 CFU/ml)

· The World's only molecular diagnostics product capable of simultaneously detecting TB and MTBDR-RIF when monitoring treatment.

More Less

Product category: Immuno assay testing

COVID19+ 9G test™

· N, ORF3a, and RdRp genes are WHO recommended COVID-19 gene detection regions.

· E gene is a gene found in other corona family viruses as well.

· COVID19+ 9G testTM detects N, ORF3a, and RdRp genes up to 10 copies/test.

· 10 copies/test not only allows the accurate detection of COVID-19 but also enables this test to detect recurrence earlier.

More Less

About us

Company portrait

Biometrix Technology INC. (BMT), is a biochip company that specializes in making oligonucleotide DNAChips and Genotyping kits for early detection of viral or bacterial infections. BMT has raised a fund from Korean venture investment syndicates and spent its energy in pursuing the major R & D in the field of DNA Testing. Focusing on new technologies, new markets for near patient diagnostic products, and new attitudes of patients and healthcare providers, Biometrix technology Inc. is going forward into the fastest growing sector of worldwide diagnostic industry whose products are transforming the practice of medicine.

The DNA test market for diagnostic tests increases at a phenomenal compounded annual growth rate, and many parts of the world market is growing at comparable rates. BMT’s special 9G DNAChips and 9G Membranes are designed to show ultrafast hybridization of more than 90% efficiency in less than 10 min at 25oC, the fastest hybridization ever reported. The 9G technology guarantees the highest grade of sensitivity and specificity in DNA-DNA binding.

The ultrafast hybridization of 9G DNAChips and 9G Membranes provides a novel platform for DNA-directed immobilization (DDI) of proteins, aptamers and small molecules. We are committed to develop and share the 9G methods and its products for early detection of various cancers and viral or bacterial infections. By further developing our innovative 9G technology, BMT would service novel platforms for the R&D of new biological active materials.